RNS Number:9725S
Libertas Capital Group PLC
21 October 2005


For immediate release                                           21 October 2005



                           LIBERTAS CAPITAL GROUP plc

                     ("Libertas Capital" or "the Company")


                INTRODUCES ASIAN PHARMACEUTICALS COMPANY TO AIM


Libertas Capital Group plc (AIM: LBR) the financial services firm, is pleased to
announce that it has successfully brought Beximco Pharmaceuticals Limited ("BPL
"), a Bangladesh -based and -listed pharmaceuticals manufacturer, to AIM,
having successfully completed an institutional placing of global depositary
receipts ("GDRs") amounting to #12m. Libertas Capital has acted as nominated
advisor and broker to BPL.

BPL manufactures and sells generic pharmaceutical formulation products, active
pharmaceutical ingredients and intravenous fluids. Following the fundraising of
#12m, the placing price will result in BPL having a post-money market
capitalisation of #60m.

Commenting on the announcement, Henry Okereke, CEO of Libertas Capital, said: 
"We are delighted to announce that we have successfully completed the IPO of
Beximco Pharmaceuticals in our role as nominated advisor and broker to the
Company. This is the first Bangladesh company to be admitted to AIM and one of
the first companies to have GDRs listed. We look forward to continuing our
partnership with Beximco as they successfully establish themselves on AIM."



For further information please contact:


Libertas Capital Group plc                                 +44 (0)20 7569 9650

Jakob Kinde, Executive Chairman
Henry Okereke, Chief Executive Officer

Grant Thornton                                             +44(0)20 7383 5100

Graeme Thom/ Fiona Reid

Buchanan Communications                                    +44(0)20 7466 5000
Charles Ryland / Mary-Jane Johnson





Notes to Editors

About Libertas Capital Group plc


Libertas Capital is a UK-based financial services firm offering its clients a
full range of dedicated independent Corporate Finance Advisory, Research and
Distribution services.

Corporate Finance services include advice on M&A, public and private fund
raising, private equity encompassing development capital, MBOs and MBIs,
valuation and exit strategy. In the Securities business Libertas Capital offers
research to corporate and institutional clients, via Equity Growth Research and
Libertas Capital Research, over a global distribution network. Libertas Capital
is focused on the small to mid cap market in the UK, Northern Europe, the Nordic
region and the US, where the Group has gained widespread experience and
developed strong relationships.

Libertas Capital concentrates primarily on growth companies across a number of
industry sectors with a particular focus on environmental sciences, technology
(software and business services) and medical technology.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCURSBRVRRRUAA
Libertas Capital (LSE:LBR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Libertas Capital Charts.
Libertas Capital (LSE:LBR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Libertas Capital Charts.